Market Cap
$3.5B
ACAD
ACADIA PHARMACEUTICALS INC
$19.95 ▲ +0.30%
Prev close $19.89Market cap$3.5B
ConsensusBuy
12-mo target$32.16 (+61.2%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)29 New Institutional Positions21 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ACAD right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (78%)
Inst. Holders
50 funds
Inst. Value
$3.7B
Inst. Activity
29 buys / 21 sells
Insider Activity
$0.00 buy / $2.2M sell
Insider Net $
-$2.2M
SEC Reports
9
Price chart 30d -28.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 11, 2026 SEC Aug 17, 2026 SEC Aug 7, 2026 SEC
Acadia Pharmaceuticals settled a stockholder derivative lawsuit related to alleged misleading statements about its pimav
8-K — Impact 3/10
Institutional activity in ACAD during 2026-Q2 shows a mixed picture: 12 buyers accumulated $180.5M (net +$122.9M) led by
INST-CLUSTER — Impact 5/10
Two ACAD insiders (CFO and EVP R&D) sold a combined $601K in open-market transactions over a 7-day window. The total rep
CLUSTER — Impact 2/10
Aug 6, 2026 Insider
Schneyer Mark C. acquired via exercise 14,292 shares
EVP, CHIEF FINANCIAL OFFICER @ $17.84 ($255.0K)
Aug 6, 2026 Insider
Schneyer Mark C. sold 5,000 shares
EVP, CHIEF FINANCIAL OFFICER @ $29.00 ($145.0K)
Aug 6, 2026 Insider
Schneyer Mark C. sold 9,292 shares
EVP, CHIEF FINANCIAL OFFICER @ $29.34 ($272.6K)
Aug 4, 2026 earnings_calendar
ACAD Q2 2026 Earnings Scheduled — 2026-08-04
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
2,580,115 shares ($65.3M)
Analyst ratings buy % +13.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
78% rate it Buy or better · 27 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 25, 2026 | Deutsche Bank | MAINTAIN | Buy | 58% |
| Sep 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Sep 25, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| Sep 25, 2026 | BMO Capital | MAINTAIN | Outperform | 53% |
| Sep 25, 2026 | Needham | MAINTAIN | Buy | 50% |
| Sep 24, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Sep 24, 2026 | Needham | REITERATE | Buy | 50% |
| Aug 25, 2026 | Deutsche Bank | MAINTAIN | Buy | 58% |
| Aug 25, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
| Aug 25, 2026 | Citigroup | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 14 | 5 | 1 | 0 | 78% | |
| Aug 1, 2026 | 7 | 14 | 5 | 1 | 0 | 78% | |
| Jul 1, 2026 | 7 | 14 | 5 | 1 | 0 | 78% | |
| Jun 1, 2026 | 7 | 14 | 5 | 1 | 0 | 78% | |
| May 1, 2026 | 7 | 14 | 5 | 1 | 0 | 78% | |
| Apr 1, 2026 | 7 | 14 | 5 | 1 | 0 | 78% | |
| Mar 1, 2026 | 6 | 14 | 6 | 1 | 0 | 74% | |
| Feb 1, 2026 | 5 | 13 | 7 | 1 | 0 | 69% |
Price targets
Where 19 covering analysts think ACAD trades over the next 12 months.
$32.16 +61.2% upside Strong Buy
Current$19.95 Low$17.00 Median$33.00 High$49.00 19 analysts
$17.00$49.00
Analyst rating Buy· 1.8/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 1 bullish, 2 bearish, 1 mixed, 5 neutral · avg impact 4.3/10.
NEUTRAL8-K3/10
Acadia Pharmaceuticals settled a stockholder derivative lawsuit related to alleged misleading statem
Sep 11, 2026
MIXEDINST-CLUSTER5/10
Institutional activity in ACAD during 2026-Q2 shows a mixed picture: 12 buyers accumulated $180.5M (
Aug 17, 2026
NEUTRALCLUSTER2/10
Two ACAD insiders (CFO and EVP R&D) sold a combined $601K in open-market transactions over a 7-day w
Aug 7, 2026
BEARISHINST-CLUSTER6/10
A bearish institutional cluster emerged in ACAD during Q3 2025: 5 major sellers reduced holdings by
Jun 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 8, 2026
Clinical Trial
OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Phase Phase 3 — TERMINATED
Aug 4, 2026
earnings_calendar
ACAD Q2 2026 Earnings Scheduled — 2026-08-04
Jul 31, 2026
short_volume
Short Volume: ACAD — 62.2% short (0.3M / 0.5M)
Short: 325,853 | Exempt: 2,158 | TRF Vol: 523,859 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Jul 29, 2026
short_volume
Short Volume: ACAD — 56.7% short (0.3M / 0.6M)
Short: 324,049 | Exempt: 10,593 | TRF Vol: 571,621 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
ftd
FTD: ACAD — 25,079 shares ($0.5M) failed to deliver
Settlement: 20260608, Price: $21.56, FTD Value: $540,703.24, ACADIA PHARMACEUTICALS INC
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.19 | $0.11–$0.33 | -55.9% | +0.0% | 10↑ 0↓ | $0.3B | 14 |
| Next Q | $0.21 | $0.14–$0.26 | 56.1% | +0.0% | 9↑ 2↓ | $0.4B | 14 |
| Current FY | $0.60 | $0.50–$0.72 | -27.8% | +0.0% | 13↑ 0↓ | $1.3B | 14 |
| Next FY | $0.89 | $0.22–$1.87 | 48.3% | -0.2% | 8↑ 5↓ | $1.4B | 14 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.185 | — |
| 7d ago | $0.185 | — |
| 30d ago | $0.185 | — |
| 60d ago | $0.130 | +0.056 |
| 90d ago | $0.126 | +0.059 |
Institutional ownership
Which big funds own ACAD (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $3.7B total value (147,075,117 shares) as of 2026-Q2. Top holders: NOMURA, BAKER, BlackRock,. Net buying activity: 29 institutions added/increased vs 21 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| BAKER BROS. ADVISORS LP | 42,912,904 | $1.1B | 29.2% | — |
| BlackRock, Inc. | 22,515,173 | $569.6M | 15.3% | — |
| STATE STREET CORP | 9,076,212 | $229.6M | 6.2% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8,838,450 | $223.6M | 6.0% | — |
| RTW INVESTMENTS, LP | 7,144,524 | $180.8M | 4.9% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,763,750 | $145.8M | 3.9% | — |
| DIMENSIONAL FUND ADVISORS LP | 3,694,988 | $93.5M | 2.5% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 3,358,129 | $85.0M | 2.3% | — |
| GOLDMAN SACHS GROUP INC | 2,580,115 | $65.3M | 1.8% | ADD +65.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | ADD | 1,557,804 | 2,580,115 | +65.6% | $65.3M |
| Qube Research & Technologies Ltd | DOUBLED | 950,299 | 2,446,610 | +157.5% | $61.9M |
| CITADEL ADVISORS LLC | DOUBLED | 622,760 | 2,182,177 | +250.4% | $55.2M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | 1,569,491 | 1,969,445 | +25.5% | $49.8M |
| MARSHALL WACE, LLP | DOUBLED | 76,187 | 1,764,838 | +2216.5% | $44.7M |
| D. E. Shaw & Co., Inc. | DOUBLED | 729,836 | 1,697,937 | +132.6% | $43.0M |
| NORGES BANK | NEW | — | 1,623,308 | — | $41.1M |
| Nuveen, LLC | ADD | 1,036,987 | 1,348,192 | +30.0% | $34.1M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,724,196 | 1,282,596 | -25.6% | $32.4M |
| FRED ALGER MANAGEMENT, LLC | TRIM | 1,277,151 | 648,611 | -49.2% | $16.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net -$2.2M — $0.00 bought, $2.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | EXERCISE | 14,292 | $17.84 | $255.0K |
| Aug 6, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | SELL | 5,000 | $29.00 | $145.0K |
| Aug 6, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | SELL | 9,292 | $29.34 | $272.6K |
| Aug 5, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | EXERCISE | 5,849 | $17.84 | $104.3K |
| Aug 5, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | SELL | 5,849 | $29.00 | $169.6K |
| Jul 30, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | SELL | 16,508 | $26.13 | $431.4K |
| Jul 30, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | SELL | 50 | $26.17 | $1.3K |
| Jul 29, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | EXERCISE | 32,272 | — | — |
| Jun 26, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | SELL | 11,421 | $26.08 | $297.9K |
| May 29, 2026 | BAKER BROS. ADVISORS LP | Director | AWARD | 18,622 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ACAD.
Shares short
9,666,972
Settlement Sep 15, 2026
Change vs prior
-0.8%
Semi-monthly cycle
Days to cover
7.2
At avg daily volume
Of shares outstanding
≈5.6%
Estimate — not % of float
All ACAD filing & press-release reports (9)
- 8-K reportSep 11, 2026
- INST-CLUSTER reportAug 17, 2026
- CLUSTER reportAug 7, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 6, 2026
- CLUSTER reportMay 5, 2026
- CLUSTER reportMar 27, 2026
- 8-K reportMar 5, 2026
- 8-K reportFeb 25, 2026